CLASS II ONGOING Device recall · Reported 31 May 2023 · FDA Enforcement Report

Vitros Chemistry Products HbA1c Reagent Kit- IVD recalled

Ortho-Clinical Diagnostics is recalling Vitros Chemistry Products HbA1c Reagent Kit- IVD for the quantitative determination of, distributed nationwide in the US. The recall was initiated on 17 Apr 2023 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesUDI-DI: 10758750030729 Lot Number/Expiry: 29-9396 2023-SEP-02; 29-9466 2023-SEP-02; 30-9647 2023-NOV-25; 30-9803 2023-NOV-25; 31-9648 2024-JAN-24; 32-9925 2024-APR-14; 33-1097 2024-JUL-18; 33-1105 2024-JUL-18; 33-1228 2024-JUL-18; 34-1345* 2024-OCT-17. All lots within expiry (listed above) as well as future lots until your laboratory receives an additional notification from Ortho
Quantity recalled23751

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-1628-2023
FDA event ID
92254
Recalling firm
Ortho-Clinical Diagnostics, Raritan, NJ
Classification
Class II
Status
Ongoing
Recall initiated
17 Apr 2023
FDA classified
24 May 2023
Reported
31 May 2023
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Other Reasons

Timeline

17 Apr 2023Recall initiated by company
24 May 2023Classified by FDA+37 days
31 May 2023Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Potential for both unexpected positive and negative HbA1c results, may result in misdiagnosis

Product as listed by the FDA

VITROS Chemistry Products HbA1c Reagent Kit- IVD for the quantitative determination of percent glycated hemoglobin A1c (DCCT/NGSP) and mmol/mol hemoglobin A1c (IFCC) in human whole blood. Product Code: 6842905

Where it was distributed

US Nationwide- Worldwide Distribution. Foreign: Australia Belgium Brazil Bermuda HM12 Canada L3R 4G5 Chile China Colombia Denmark France France Germany India Italy Japan Mexico Norway Portugal Russia Singapore 609917 Spain Sweden The Netherlands United Kingdom

Nationwide

Questions about this recall

Why was it recalled?

Potential for both unexpected positive and negative HbA1c results, may result in misdiagnosis

Which lots are affected?

UDI-DI: 10758750030729 Lot Number/Expiry: 29-9396 2023-SEP-02; 29-9466 2023-SEP-02; 30-9647 2023-NOV-25; 30-9803 2023-NOV-25; 31-9648 2024-JAN-24; 32-9925 2024-APR-14; 33-1097 2024-JUL-18; 33-1105 2024-JUL-18; 33-1228 2024-JUL-18; 34-1345* 2024-OCT-17. All lots within expiry (listed above) as well as future lots until your laboratory receives an additional notification from Ortho

Where was it sold?

US Nationwide- Worldwide Distribution. Foreign: Australia Belgium Brazil Bermuda HM12 Canada L3R 4G5 Chile China Colombia Denmark France France Germany India Italy Japan Mexico Norway Portugal Russia Singapore 609917 Spain Sweden The Netherlands United Kingdom

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Ortho-Clinical Diagnostics

All 311

Other Test Kits & Diagnostics recalls

All 2,656